Erschienen in:
01.12.2023 | Review Article
Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis
verfasst von:
Rongjin Chen, Changshun Chen, Bin Geng, Chenhui Yang, Hefang Xiao, Fei Yang, Hao Wang, Yayi Xia
Erschienen in:
Archives of Osteoporosis
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Osteoporosis is a metabolic bone disease that commonly results in middle-aged and elderly people following fractures. Odanacatib (ODN), a potential osteoporosis medication, was stopped in the Long-term Odanacatib Fracture Trial (LOFT) phase III study because it increased the risk of stroke. Herein, we conducted a systematic review and meta-analysis to further assess the efficacy and safety of ODN in osteoporosis treatment.
Methods
We searched the PubMed, EMBASE, Cochrane Library, and Web of Science, using the core search terms “osteoporosis” and “odanacatib.” The primary outcomes were the percentage change in markers of bone turnover and bone formation as well as that in the bone mineral density (BMD) of the lumbar spine, hip, femoral neck, and greater trochanter. The secondary outcome was the risk of adverse events (AEs), used to explore the safety of ODN.
Results
Ten articles—all double-blinded, randomized, placebo-controlled trials—were included. All trials were considered to be of high quality if they met the inclusion and exclusion criteria. We found that ODN increases BMD in the lumbar spine, total hip, and femoral neck, whereas it decreases the concentration of serum C-telopeptides of type I collagen (sCTx) and urinary N-telopeptide/creatinine ratio (uNTx/Cr). We found no significant differences in total, drug-related, serious, or skin AEs between the ODN and control groups. However, significant differences in fracture and stroke AEs were found between the ODN and control groups.
Conclusion
ODN is an appealing long-term osteoporosis treatment method; however, further research should focus on the potential increased risk of fracture and stroke.